Cellebrite Announces Results of Completed Redemption of All Outstanding Warrants
September 18, 2024 16:15 ET
|
Cellebrite DI Ltd
TYSONS CORNER, Va. and PETAH TIKVA, Israel, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT) (“Cellebrite,” the “Company” or “we”), a global leader in premier Digital...
Abacus Life Policy Value Calculator Surpasses Milestone of 150,000 Policy Valuations
September 18, 2024 16:15 ET
|
Abacus Life Settlements
ORLANDO, Fla., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leading global alternative asset manager focused on lifespan-based financial...
ECD Auto Design Announces CFO Transition and Board Restructure
September 18, 2024 16:15 ET
|
E.C.D. Automotive Design
KISSIMMEE, Fla., Sept. 18, 2024 (GLOBE NEWSWIRE) -- ECD Automotive Design, Inc. (Nasdaq: ECDA) (“ECA Auto Design” or the “Company”), an industry leader in delivering restored, modified and...
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2024
September 18, 2024 16:15 ET
|
Nanobiotix S.A.
NBTXR3 activé par radiothérapie suivi d’un anti-PD-1 a montré un profil de sécurité favorable, un contrôle de la maladie et une réponse tumorale chez les patients naïfs et résistants aux anti-PD-1,...
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
September 18, 2024 16:15 ET
|
Nanobiotix S.A.
RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune...
America’s Car-Mart, Inc. Announces Proposed $65 Million Underwritten Public Offering Of Common Stock
September 18, 2024 16:12 ET
|
America's Car-Mart, Inc.
ROGERS, Ark., Sept. 18, 2024 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) (“Car-Mart” or the “Company”), a large publicly held automotive retailer focused exclusively on the...
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
September 18, 2024 16:09 ET
|
SciSparc Ltd
Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel will take part in the trial TEL AVIV,...
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
September 18, 2024 16:05 ET
|
Enliven Therapeutics, Inc.
BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and...
Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer
September 18, 2024 16:05 ET
|
Trinity Biotech plc
DUBLIN, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including...
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
September 18, 2024 16:05 ET
|
4D Molecular Therapeutics, Inc.
4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on longest available follow-up data In broad population...